HDx

The Next Horizon in Dialysis is Closer Than You Think

Contact Me
HDx_2020_image2_570x570_v3.jpg

Expand renal possibilities for all HD patients

Expanded haemodialysis (HDx) therapy is the next evolution in haemodialysis that brings us a step closer to the natural kidney.1 HDx enabled by Theranova* features an innovative membrane for higher permeability compared to HD and HDF to enable efficient removal of large middle molecules (25 kDa to <60 kDa).2,3,4
Some of these large uraemic toxins have been linked to inflammation, cardiovascular disease and other co-morbidities in dialysis patients.5,6

There is a growing body of evidence showing that HDx can improve key patient reported outcomes

Man_Whoman_Smiling

The majority of people on haemodialysis will experience some degree of symptom burden

Self-reported symptom burden is associated with higher mortality, lower quality of life, and depression in individuals' on HD

Whoman_Whoman_Smiling

Patient related outcomes have a significant impact on patients

  • 40% have Severe Pruritus13, 14
  • Up to 70% have Restless Legs15
  • Symptom Burden is often under recognised16

SONG-HD highlights fatigue as the top concern for individuals, which can be exacerbated by pruritus and restless leg syndrome

HDx therapy may improve patient-reported outcomes including: uremic pruritus, restless leg syndrome and recovery time. 

David

Find out how Theranova improved patient-reported outcomes for Dennis

HDx, theranova, theranova dialyzer, dialysis, HDx, expanded hemodialysis, expanded HD, patient story

Find out how Theranova improved patient-reported outcomes for Brenda

Robert

Find out how Theranova improved patient-reported outcomes for Robert

Find out what the HDx KOL have presented about Theranova over the time

Introducing Theranova for Expanding Hemodialysis

Introducing Theranova for Expanding Hemodialysis (HDx) Prof. Claudio Ronco, Italy September 9th 2020

Baxter HDx Unmet needs in HD

Expanded HD: Exploring the Unmet Need & Medical  Evidence Prof. Chris Mclntyre, Ontario, Canada September 21st 2020 

HDX

Can HDx Impact Symptom Burden and Quality of Life?

HDx therapy delivers meaningful and relevant innovation for dialysis patients

1_HDx_2020_planets_customer_support_600x260.jpg

Safety Evidence

HDx therapy enabled by the Theranova dialyser provides superior removal of large middle molecule uraemic toxins compared to conventional HD and HDF while retaining essential proteins and maintaining stable albumin levels.2,3,7

2_HDx_2020_planets_dialyzer_600x260.jpg

Performance

HDx therapy enabled by the innovative Theranova dialyser with increased nominal pore size, targets the efficient removal of large middle molecule uraemic toxins without the need for a more complex setup than regular HD.1,6

3_HDx_2020_planets_clipboard_600x260.jpg

Clinical Effectiveness

HDx therapy addresses pathophysiological responses and clinical outcomes that challenge patients undergoing haemodialysis for treatment of end stage kidney disease.8

4_HDx_2020_planets_man_woman_600x260.jpg

Patient-Reported Measures

HDx therapy may improve patient-reported outcomes related to quality of life aspects of kidney disease, including symptom burden, restless legs syndrome criteria, pruritus and dialysis recovery time.4,8,9

5_HDx_2020_planets_cogs_600x260.jpg

Operational Efficiency

With HDx therapy, not only can Theranova provide advanced performance compared to HD and HDF along with clinical and patient-reported benefits but HDx therapy can be prescribed using regular HD workflow and infrastructure.6,10 

 

6_HDx_2020_planets_graph_600x260.jpg

Economics

While HDx therapy may offer the potential to improve access to care and to help improve the effectiveness and quality of care, HDx therapy may simultaneously offer dialysis service providers and healthcare systems alike the opportunity to reduce the total cost of care.11,12 

Baxter's Commitment to You

HDx therapy provides high-performance haemodialysis treatments by targeting the efficient removal of large and conventional middle molecules (500 Da to <60 kDa), many of which have been linked to the development of inflammation, cardiovascular disease and other comorbidities in dialysis patients.1,3,4

The Healthcare Concern

Conventional and large middle molecules effect a range of biological functions including inflammation and cardiovascular risk. The retention of these molecules has been associated with higher mortality in chronic kidney disease patients.6

The Challenge

Traditional high-flux membranes prescribed for use in haemodiafiltration and high-flux haemodialysis treatments have limited capability to remove conventional and large middle molecule uraemic toxins.1,5,6

HDx_page_600x260.

HDx Therapy Brochure

Here you can find the HDx therapy brochure with more information about prescribing HDx for your haemodialysis patients.

600x260_02.png

HDx Therapy Specification Sheet

Here you can find the detailed profiles of Theranova dialysers.

Reference Library

Hear from patients, nephrologists, and nurses alike as they share their experience prescribing HDx. Be reassured by the pioneering commitment of Baxter to dialysis patients the world over and learn how Theranova dialysers are made.

HDx Evidence Compendium

On-going research and clinical reporting are an integral part of the HDx journey. Explore the expanding evidence related to HDx enabled by Theranova that nephrologists around the world continue to generate.

Related Products

Important Safety Information

Theranova dialysers are indicated for treatment of chronic and acute renal failure by haemodialysis.
*Do not use Theranova dialysers in HDF or HF mode.
For safe and proper use of this device, please refer to Instructions for Use.

CE 2797